ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Can brain-to-tumour outer interface radiomics improve the efficiency of MRI in predicting the brain invasion of meningiomas?
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundBrain invasion serves as an independent diagnostic criterion for the diagnosis of WHO grade 2 meningiomas. This study aimed to evaluate the value of radiomic models constructed with features extracted from different regions of the brain-to-tumor interface to predict potential brain invasion of meningiomas.
methodsThe cohort of this retrospective multicenter study included 915 consecutive patients from three centers with histopathologically confirmed meningiomas. Brain invasion status was determined separately using predefined criteria based primarily on histopathological findings, with operative records used as supplementary information. Nine radiomic models were developed using radiomic features extracted from nine different regions of interest: 3-5 mm regions of the brain-to-tumor interface (BTI), brain-to-tumor inner interface (BTII), and brain-to-tumor outer interface (BTOI). The features were derived from T1W, T2-FLAIR, and CE-T1W images. A logistic regression classifier was trained for model development. Model discrimination was evaluated via receiver operating characteristic (ROC) analysis, while clinical utility and incremental predictive value were quantified using decision curve analysis (DCA) and the integrated discrimination improvement (IDI) index.
resultsAs compared to models constructed with features from the 3-5 mm BTII and BTI regions, the BTOI radiomic models demonstrated enhanced predictive capability for meningioma brain invasion. The area under the curve (AUC) values for the 3-, 4-, and 5-mm BTOI models were 0.845, 0.845, and 0.905 with the test cohort, and 0.818, 0.825, and 0.874 with the external validation cohort, respectively. DCA confirmed the clinical superiority of the BTOI models, which provided the highest net benefit across various threshold probabilities. Moreover, the IDI index indicated that the BTOI features offered statistically significant incremental value for invasion risk stratification as compared to the BTII and BTI models (p < 0.05).
conclusionsThe BTOI radiomic models demonstrated superior performance in predicting brain invasion in meningiomas compared with models constructed from the BTI and BTII regions. These findings suggest that the peritumoral brain tissue adjacent to the tumor may contain particularly informative imaging characteristics related to invasion and provide imaging-based support for optimizing ROI delineation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.